Jacobs Levy Equity Management’s iRadimed IRMD Stock Holding History

Jacobs Levy Equity Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$836K	Hold	8,684	–	–	﹤0.01%	744
2025 Q4	$845K	Sell	8,684 -362	-4%	-$31.1K	﹤0.01%	715
2025 Q3	$644K	Sell	9,046 -198	-2%	-$13.2K	﹤0.01%	785
2025 Q2	$553K	Sell	9,244 -13,963	-60%	-$765K	﹤0.01%	869
2025 Q1	$1.22M	Buy	23,207 +123	+0.5%	+$6.91K	﹤0.01%	774
2024 Q4	$1.27M	Sell	23,084 -1,695	-7%	-$89.2K	﹤0.01%	680
2024 Q3	$1.25M	Buy	24,779 +472	+2%	+$21.8K	﹤0.01%	687
2024 Q2	$1.07M	Buy	24,307 +11,410	+88%	+$485K	﹤0.01%	724
2024 Q1	$567K	Sell	12,897 -42	-0.3%	-$1.86K	﹤0.01%	806
2023 Q4	$614K	Sell	12,939 -128	-1%	-$5.38K	﹤0.01%	801
2023 Q3	$580K	Sell	13,067 -1	-0%	-$46	﹤0.01%	772
2023 Q2	$624K	Buy	+13,068	New	+$589K	﹤0.01%	782
2019 Q2	–	Sell	-13,188	Closed	-$370K	–	984
2019 Q1	$370K	Buy	13,188 +4,780	+57%	+$125K	0.01%	817
2018 Q4	$206K	Buy	+8,408	New	+$226K	﹤0.01%	874

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's IRMD Position: Q1 2026 in Review

Jacobs Levy Equity Management held its iRadimed (IRMD) position steady in Q1 2026 at 8,684 shares worth $836K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Jacobs Levy Equity Management first reported a position in IRMD in Q4 2018 and has held it in 14 quarters since. The position peaked at $1.27M in Q4 2024. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Jacobs Levy Equity Management held 8,684 shares of iRadimed worth $836K as of Q1 2026.
Jacobs Levy Equity Management left its iRadimed share count unchanged in Q1 2026.
iRadimed made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #744 holding.
Jacobs Levy Equity Management first reported a position in iRadimed in Q4 2018 and has held it in 14 quarters since.
Jacobs Levy Equity Management's iRadimed position peaked at $1.27M in Q4 2024.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.